A Study in Participants With Non-cirrhotic NASH With Fibrosis
Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial.
Participants will be in the trial for up to 22 weeks, including a screening period lasting up
to 6 weeks, a 12-week treatment period, and a 4-week safety follow-up period
Participants are not expected to directly benefit from treatment during this trial.
Participants will help researchers learn more about and how to develop AZD4831 to treat NASH.